Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 112,089

Document Document Title
WO/2015/196401A1
Disclosed is a use of α-Asarone in preparing drugs for preventing and treating Alzheimer's disease. As indicated by the experiments, α-Asarone has an obvious inhibiting effect on palsy phenotype in pathological models of animals with A...  
WO/2015/197098A1
The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encodi...  
WO/2015/197194A3
The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encodi...  
WO/2015/197079A1
The present invention is directed to a composition comprising a buspirone metabolite, alone or in combination with a second active ingredient, for use in the treatment of movement disorders.  
WO/2015/200594A2  
WO/2015/200322A1
In certain embodiments, the invention relates to methods for treating migraine (e.g. episodic migraine, chronic migraine, retinal migraine, ophthalmoplegic migraine, acephalgic migraine, migrainous disorder, menstrual migraine, abdominal...  
WO/2015/199537A1
The invention relates to the field of therapies for and prevention of mental disorders, more particularly therapies for depression, burn-out and cognitive disorders. Specifically, the invention relates to a new mineral composition compri...  
WO/2015/198078A1
The present invention relates to the use of 7-hydroxy-cannabidol (7-OH-CBD) and / or 7-hydroxy-cannabidivarin (7-OH-CBDV) in the treatment of epilepsy. Preferably the cannabinoid metabolites are isolated from plants to produce a highly p...  
WO/2015/197735A1
Herein is reported a non-covalent complex of a haptenylated antibody that specifically binds to human Tau(pS422) and an anti-blood brain barrier receptor/hapten bispecific antibody.  
WO/2015/200534A2
Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.  
WO/2015/199206A1
The present invention relates to a compound represented by formula (I), a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the compound or the salt. (In the formula, R1 represents a hydrogen atom or t...  
WO/2015/199234A1
 Provided is a novel salt of an α-halogen-substituted thiophene compound that has powerful LPA receptor antagonistic action and that is useful as a pharmaceutical product. A salt represented by general formula (1) [In the formula: R...  
WO/2015/196402A1
A preparation method for a traditional Chinese medicine composition and use thereof in preparing medicines for prevention or treatment of Alzheimer's disease. The traditional Chinese medicine composition mainly comprises the following ac...  
WO/2015/200534A3
Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.  
WO/2015/200472A1
Embodiments of the invention relate generally to the field of transdermal delivery and more specifically to transdermal patches containing rasagiline for the treatment of depression, Parkinson's disease, and other nervous system conditions.  
WO/2015/200766A2
The present invention provides compounds and compositions which are positive allosteric modulators of GABA-A receptors that selectively target the peripheral nervous system and organs of the body, and which do not pass through the blood-...  
WO/2015/199503A1
The present invention relates to a pharmaceutical composition for preventing and treating degenerative brain diseases, containing 5-[(3-chlorophenyl)amino]benzo [c]-2,6-naphthyridine-8-carboxylic acid (CX-4945) as an active ingredient. S...  
WO/2015/197567A1
The present invention is concerned with 2-oxo-2,3-dihydro-indoles of general formula (I) wherein Ar1 is phenyl or a five or six membered heteroaryl group, containing one, two or three heteroatoms, selected from N, S or O, wherein the N-h...  
WO/2015/200682A1
Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurologica...  
WO/2015/192714A1
The present invention relates to a pyrroloimidazole ring derivative and a medical application thereof, and particularly to a pyrroloimidazole ring derivative represented by general formula (I) or a stereoisomer thereof, a pharmaceuticall...  
WO/2015/193667A1
The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of "treatment-resistant epilepsy" (TRE). In particular, the disclosure relates to the use of CBD of t...  
WO/2015/193417A1
The present inventor has found that glioblastoma cells respond in unique ways to prolactin (PrI) receptor antagonists. The reaction of glioblastoma cells to treatment with PrI receptor antagonists is based on the presence and function of...  
WO/2015/193228A1
The invention relates to BET-protein-inhibiting 1,4-dihydropyrido[3,4-b]pyrazinones with para-substituted aromatic amino or ether groups of general formula (I), in which A, X, Y, R1, R2, R3, R4, R5, R6, and n have the meanings indicated ...  
WO/2015/194564A1
 Provided are a composition, food, and drug for enhancing memorization learning function and/or cognitive function. Using a peptide including any one amino acid sequence of SEQ ID NOS: 1-16 as an active ingredient makes it possible to ...  
WO/2015/193255A1
The present invention is directed to novel compounds of Formula (I), pharmaceutically acceptable salts or solvates thereof, and their use.  
WO/2015/192701A1
An amino pyranoid ring derivative represented by general formula (I), or stereoisomers, pharmaceutically acceptable salts, prodrugs, pharmaceutical compositions containing the derivative and medicinal use thereof in preparing dipeptidyl ...  
WO/2015/193219A1
The invention relates to BET-protein-inhibiting, in particular BRD4-inhibiting 3,4-dihydropyrido[2,3-b]pyrazinones with meta-substituted aromatic amino or ether groups of general formula (I), in which A, X, Y, R1, R2, R3, R4, R5, R6, and...  
WO/2015/193457A1
The present invention relates to the use of a direct Factor XII (FXII) inhibitor in the treatment of a neurotraumatic disorder resulting from a traumatic injury of the brain (traumatic brain injury, TBI) or the spinal cord (spinal cord i...  
WO/2015/193217A1
The invention relates to BET-protein-inhibiting, in particular BRD4-inhibiting, 3,4-dihydropyrido[2,3-b]pyrazinones with para-substituted aromatic amino or ether groups of general formula (I), in which A, X, Y, R1, R2, R3, R4, R5, R6, an...  
WO/2015/194928A1
The invention relates to the compounds 3-(1´,1´ -dimethylallyl)-herniarin (1) y 3- (1,1´-dimethyl-3´ nitro allyl-herniarin] (3) (NHR) derived from coumarin, which have excellent antidepressant activity. The compound 3- (1,1´-dimethy...  
WO/2015/194926A1
Gabapentin and lysine clonixinate (CLG) can be combined to relieve neuropathic pain caused by both diabetic neuropathy and nerve injury. The CLG combination creates a synergy in the antiallodynic effect when the allodynia has been genera...  
WO/2015/195474A1
Provided herein are hydroxypyridone derivatives, for example, a compound of Formula I, and pharmaceutical compositions thereof. Also provided herein are methods for treating, preventing, or ameliorating one or more symptoms of an inflamm...  
WO/2015/192228A1
A composition comprising a Mixed Anthocyanin Formulation (MAF), wherin said MAF comprises four anthocyanidins/anthocyanins (e.g. kuromarin/cyanidin (Kur), oenin/malvidin (Oen), callistephin/pelargonidin (Cal), and peonidin (Peo) that inh...  
WO/2015/192772A1
A pharmaceutical application of an NMDA receptor antagonist. The NMDA receptor antagonist and a pharmaceutically acceptable salt or a pharmaceutical composition thereof are used to prepare drugs for treating or preventing central nervous...  
WO/2015/193668A1
The present disclosurerelates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering withetiologies that include: ...  
WO/2015/193229A1
The invention relates to BET-protein-inhibiting 1,4-dihydropyrido[3,4-b]pyrazinones with meta-substituted aromatic amino or ether groups of general formula (I), in which A, X, Y, R1, R2, R3, R4, R5, R6, and n have the meanings indicated ...  
WO/2015/192198A1
A method is described for treating a peroxisome biogenesis disorder by administering to an individual in need thereof an effective amount of an autophagy inhibitor. Uses, compositions, and commercial packages are also described. The pero...  
WO/2015/195880A1
The invention provides compounds of Formula (I) and pharmaceutically-acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.  
WO/2015/194494A1
The present invention addresses the problem of providing: a cell structure for use in the treatment of brain injury, which does not contain glutaraldehyde and can exert a sufficient therapeutic effect on brain injury; a method for produc...  
WO/2015/192804A1
A pharmaceutical composition for preventing and treating senile dementia and a preparation method therefor. The active ingredients of the pharmaceutical composition are prepared from the following raw materials in weight part: 20 to 50 p...  
WO/2015/194954A1
The present invention relates to a 6,7-dioxyalkyltetrahydroisoquinoline compound, or a salt or solvate thereof according to formula I: (formula I), (I) wherein R represents hydrogen or a fluorinated alkyl group, and R2 and R3 independent...  
WO/2015/190568A1
The present invention relates to a medicine for preventing and/or treating stress-induced diseases, said medicine being characterized in that (1S)-2-acetyl-1-(4-chloro-2-methoxyphenyl)-5-fluoro-1,2,3,9- tetrahydrospiro[β-carboline-4,1'-...  
WO/2015/189778A1
The present invention relates to a new agomelatine composition, particularly agomelatine in solution which isadsorbed on an inert carrier or directly formulated. Another subject-matter of the invention is a solid form made of an agomelat...  
WO/2015/191745A1
The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, or a mixture thereof, wherein n, m, q, A', W1, W2, W3, R1, R2, and R3 are described herein. The compounds are inhibitors to the...  
WO/2015/191726A1
The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein n, W, A', B', R1, R2, and R3 are described herein. The compounds are inhibitors to the ...  
WO/2015/188280A1
A method of treating or preventing depressed mood is describe, such as for treating or preventing postpartum blues or depression or other conditions associated with increased MAO-A levels. The method comprises administering to a subject ...  
WO/2015/191401A1
The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various di...  
WO/2015/188368A1
Pyrrolopyridine compounds of formula (I) or their pharmaceutically acceptable salts are disclosed, which may be suitable for imaging tau aggregates, b-sheet aggregates, beta-amyloid aggregates or alpha- synuclein aggregates, and hence ar...  
WO/2015/191934A3
Engineered agents or multivalent and multispecific binding proteins capable of penetrating the cells or tissue of the blood-brain barrier (BBB) are provided, along with methods of making and uses in the prevention, diagnosis, and/or trea...  
WO/2015/191707A3
Disclosed are particles comprising a complex of nicotine and cerium oxide and a biodegradable coating comprising agglutinin. Also disclosed is a method of treating or preventing neurodegenerative or neurological disorders in a mammal in ...  

Matches 701 - 750 out of 112,089